Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CSTL 
Castle Biosciences Inc (CSTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CSTL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $35.62
1 Year Target Price $35.62
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.85% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 621.36M USD | Price to earnings Ratio - | 1Y Target Price 35.62 |
Price to earnings Ratio - | 1Y Target Price 35.62 | ||
Volume (30-day avg) 9 | Beta 1.07 | 52 Weeks Range 14.59 - 35.84 | Updated Date 09/15/2025 |
52 Weeks Range 14.59 - 35.84 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.73% | Operating Margin (TTM) -4.93% |
Management Effectiveness
Return on Assets (TTM) -2.79% | Return on Equity (TTM) -2.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 382779379 | Price to Sales(TTM) 1.79 |
Enterprise Value 382779379 | Price to Sales(TTM) 1.79 | ||
Enterprise Value to Revenue 1.11 | Enterprise Value to EBITDA 11.75 | Shares Outstanding 29008300 | Shares Floating 26758109 |
Shares Outstanding 29008300 | Shares Floating 26758109 | ||
Percent Insiders 2.9 | Percent Institutions 93.08 |
Upturn AI SWOT
Castle Biosciences Inc
Company Overview
History and Background
Castle Biosciences was founded in 2005 and is focused on providing diagnostic and prognostic tests to improve health outcomes. They develop and commercialize innovative tests for cancers.
Core Business Areas
- Dermatology: Provides tests for melanoma, cutaneous squamous cell carcinoma, and other skin cancers, aiding in risk assessment and treatment decisions.
- Gastroenterology: Offers tests to improve the management of Barrett's esophagus, a precancerous condition.
- DecisionDx-UM: A gene expression profile test used to predict the risk of metastasis in patients with uveal melanoma.
Leadership and Structure
Derek J. Maetzold serves as the President and CEO. The company has a traditional corporate structure with departments for R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- DecisionDx-Melanoma: A gene expression profile test used to predict the risk of metastasis in cutaneous melanoma patients. Market share is significant in the cutaneous melanoma prognostic testing market. Competitors include Myriad Genetics (MYGN) and DermTech (DMTK).
- DecisionDx-SCC: A gene expression profile test to predict the risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients. Competitors include DermTech (DMTK).
- DecisionDx-UM: A gene expression profile test used to predict the risk of metastasis in patients with uveal melanoma. Has a significant portion of the UM testing market. No direct competitors are visible.
Market Dynamics
Industry Overview
The diagnostic testing market is growing, driven by advancements in genomics and personalized medicine. Demand for prognostic tests in oncology is increasing.
Positioning
Castle Biosciences is positioned as a leader in personalized genomic information for dermatologic cancers and other cancers, with a focus on high-value, clinically actionable tests. Their competitive advantage lies in their proprietary gene expression profile technology and extensive clinical validation data.
Total Addressable Market (TAM)
The total addressable market for Castle Biosciencesu2019 tests is estimated to be in the hundreds of millions of dollars, encompassing melanoma, SCC, and other cancer types. They are positioned to capture a substantial portion of this market with their expanding product portfolio.
Upturn SWOT Analysis
Strengths
- Proprietary gene expression profiling technology
- Strong clinical validation data
- Focus on high-value, clinically actionable tests
- Experienced management team
- Established relationships with key opinion leaders
Weaknesses
- Reliance on a limited number of products
- Reimbursement risks from payers
- Intense competition in the diagnostics market
- Dependence on third-party laboratories for processing tests
- Relatively small company size
Opportunities
- Expansion into new cancer types and indications
- Development of companion diagnostics
- Strategic partnerships and acquisitions
- Increasing adoption of personalized medicine
- Growing awareness of the importance of prognostic testing
Threats
- Changes in reimbursement policies
- Emergence of competing technologies
- Regulatory hurdles
- Economic downturns affecting healthcare spending
- Patent challenges
Competitors and Market Share
Key Competitors
- MYGN
- DMTK
Competitive Landscape
Castle Biosciences has a competitive advantage in its proprietary gene expression profiling technology. However, it faces competition from larger, more established companies like Myriad Genetics and DermTech. Castle Biosciences needs to continue to innovate and expand its product portfolio to maintain its competitive position.
Major Acquisitions
MyPath Laboratories
- Year: 2021
- Acquisition Price (USD millions): 45
- Strategic Rationale: The acquisition of MyPath Laboratories expanded Castle Biosciences' portfolio into hematopathology and other diagnostic areas.
Growth Trajectory and Initiatives
Historical Growth: Castle Biosciences has experienced significant revenue growth in recent years, driven by increasing adoption of its tests and expansion into new markets.
Future Projections: Analysts project continued revenue growth for Castle Biosciences, driven by increasing demand for its tests and expansion into new indications.
Recent Initiatives: Recent initiatives include the acquisition of MyPath Laboratories, expansion of the DecisionDx-SCC test, and ongoing clinical studies.
Summary
Castle Biosciences is a diagnostic company focused on dermatologic and other cancers. It has strong technology and clinical validation, driving revenue growth. However, it faces reimbursement risks, competition, and dependence on a limited number of tests. Future growth depends on expanding its product portfolio and navigating the changing healthcare landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share and financial data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Castle Biosciences Inc
Exchange NASDAQ | Headquaters Friendswood, TX, United States | ||
IPO Launch date 2019-07-25 | Founder, CEO, President & Director Mr. Derek J. Maetzold | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 798 | Website https://castlebiosciences.com |
Full time employees 798 | Website https://castlebiosciences.com | ||
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.